Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Zhao, Baohong ^a   Ivashkiv, Lionel B ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; COLONY STIMULATING FACTOR; CYTOKINE; DISINTEGRIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX METALLOPROTEINASE 17; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN P100; STAT1 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRIGGERING RECEPTOR EXPRESSED BY MYELOID CELL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRITIS; BONE REMODELING; CALCIUM SIGNALING; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ESCHERICHIA COLI; GENE EXPRESSION; HOMEOSTASIS; HUMAN; MONOCYTE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; TH17 CELL; TH2 CELL; ANIMAL; CYTOLOGY; GENETIC TRANSCRIPTION; IMMUNOLOGY; METABOLISM; OSTEOCLAST;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CYTOKINES; HUMANS; OSTEOCLASTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 81255213678     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3379     Document Type: Review

References (67)

1. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 2011, 13:235.
2. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264. 10.1016/j.bone.2006.09.023, 17098490.
3. Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 2006, 281:2414-2429.
4. Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A, Miyamoto Y, Eto T, Yasuda H, Nakamichi Y, Kim N, Katagiri T, Suda T, Kamijo R. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 2007, 120:573-579. 10.1111/j.1365-2567.2006.02538.x, 2265899, 17343616.
5. Wei S, Wang MW, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6622-6630. 10.1074/jbc.M104957200, 11719504.
6. Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, Hamilton JA. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta. Bone 2007, 40:323-336. 10.1016/j.bone.2006.09.003, 17055352.
7. Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, Ozaki S, Asaoka K, Tanaka E, Moriyama K, Matsumoto T. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009, 114:4517-4526. 10.1182/blood-2009-04-215020, 19762488.
8. Al-Rasheed A, Scheerens H, Srivastava AK, Rennick DM, Tatakis DN. Accelerated alveolar bone loss in mice lacking interleukin-10: late onset. J Periodontal Res 2004, 39:194-198. 10.1111/j.1600-0765.2004.00724.x, 15102048.
9. Sasaki H, Hou L, Belani A, Wang CY, Uchiyama T, Muller R, Stashenko P. IL-10, but not IL-4, suppresses infection-stimulated bone resorption in vivo. J Immunol 2000, 165:3626-3630.
10. Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 2007, 8:4. 10.1186/1471-2121-8-4, 1781937, 17239241.
11. Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 2007, 41:592-602. 10.1016/j.bone.2007.05.016, 17627913.
12. Park-Min KH, Ji JD, Antoniv T, Reid AC, Silver RB, Humphrey MB, Nakamura M, Ivashkiv LB. IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol 2009, 183:2444-2455. 10.4049/jimmunol.0804165, 2742169, 19625651.
13. Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 2010, 62:402-413. 2822027, 20112358.
14. Furukawa M, Takaishi H, Takito J, Yoda M, Sakai S, Hikata T, Hakozaki A, Uchikawa S, Matsumoto M, Chiba K, Kimura T, Okada Y, Matsuo K, Yoshida H, Toyama Y. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colonyforming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol 2009, 183:2397-2406. 10.4049/jimmunol.0802091, 19620301.
15. Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab 2007, 25:277-285. 10.1007/s00774-007-0766-8, 17704992.
16. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605. 10.1038/35046102, 11117749.
17. Ji JD, Park-Min KH, Shen Z, Fajardo RJ, Goldring SR, McHugh KP, Ivashkiv LB. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol 2009, 183:7223-7233. 10.4049/jimmunol.0900072, 2783334, 19890054.
18. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
19. Xu Z, Hurchla MA, Deng H, Uluckan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN. Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem 2009, 284:4658-4666. 2640973, 19059914.
20. Key LL, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP, Ries WL. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995, 332:1594-1599. 10.1056/NEJM199506153322402, 7753137.
21. Vignery A, Niven-Fairchild T, Shepard MH. Recombinant murine interferongamma inhibits the fusion of mouse alveolar macrophages in vitro but stimulates the formation of osteoclastlike cells on implanted syngeneic bone particles in mice in vivo. J Bone Miner Res 1990, 5:637-644.
22. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007, 117:122-132. 10.1172/JCI30074, 1697800, 17173138.
23. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749. 10.1038/416744a, 11961557.
24. Lee Y, Hyung SW, Jung HJ, Kim HJ, Staerk J, Constantinescu SN, Chang EJ, Lee ZH, Lee SW, Kim HH. The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling. Blood 2008, 111:885-893. 10.1182/blood-2007-03-082941, 17928529.
25. Ohishi M, Matsumura Y, Aki D, Mashima R, Taniguchi K, Kobayashi T, Kukita T, Iwamoto Y, Yoshimura A. Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol 2005, 174:3024-3031.
26. Hayashi T, Kaneda T, Toyama Y, Kumegawa M, Hakeda Y. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-betainhibited osteoclast formation. J Biol Chem 2002, 277:27880-27886. 10.1074/jbc.M203836200, 12023971.
27. Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM. Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alphastimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis Rheum 2010, 62:1127-1137. 10.1002/art.27312, 2854832, 20131244.
28. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004, 104:2044-2050. 10.1182/blood-2004-03-1196, 15213096.
29. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. The death receptor DR5 is involved in TRAILmediated human osteoclast apoptosis. Apoptosis 2007, 12:1623-1632. 10.1007/s10495-007-0095-3, 17558561.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001, 166:4915-4921.
31. Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 2002, 169:4732-4738.
32. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT. Interleukin-18 (interferon-gammainducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997, 185:1005-1012. 10.1084/jem.185.6.1005, 2196233, 9091574.
33. Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F, Heymann D. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 2008, 149:3688-3697. 10.1210/en.2007-1719, 18403479.
34. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 2008, 283:11535-11540. 10.1074/jbc.M607999200, 18296709.
35. Takami M, Kim N, Rho J, Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002, 169:1516-1523.
36. Zou W, Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002, 17:1211-1218. 10.1359/jbmr.2002.17.7.1211, 12096834.
37. Ha H, Lee JH, Kim HN, Kwak HB, Kim HM, Lee SE, Rhee JH, Kim HH, Lee ZH. Stimulation by TLR5 modulates osteoclast differentiation through STAT1/IFN-beta. J Immunol 2008, 180:1382-1389.
38. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 2009, 15:1066-1071. 10.1038/nm.2007, 2755267, 19718038.
39. Kikuchi T, Matsuguchi T, Tsuboi N, Mitani A, Tanaka S, Matsuoka M, Yamamoto G, Hishikawa T, Noguchi T, Yoshikai Y. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001, 166:3574-3579.
40. Itoh K, Udagawa N, Kobayashi K, Suda K, Li X, Takami M, Okahashi N, Nishihara T, Takahashi N. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 2003, 170:3688-3695.
41. Mochizuki A, Takami M, Kawawa T, Suzumoto R, Sasaki T, Shiba A, Tsukasaki H, Zhao B, Yasuhara R, Suzawa T, Miyamoto Y, Choi Y, Kamijo R. Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand. J Immunol 2006, 177:4360-4368.
42. Zaiss MM, Frey B, Hess A, Zwerina J, Luther J, Nimmerjahn F, Engelke K, Kollias G, Hünig T, Schett G, David JP. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010, 184:7238-7246. 10.4049/jimmunol.0903841, 20483756.
43. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609.
44. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009, 119:3024-3034. 10.1172/JCI38716, 2752069, 19770515.
45. Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. J Bone Miner Res 2010, 25:809-818.
46. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488. 10.1172/JCI11176, 387259, 11120755.
47. Takeshita S, Namba N, Zhao JJ, Jiang Y, Genant HK, Silva MJ, Brodt MD, Helgason CD, Kalesnikoff J, Rauh MJ, Humphries RK, Krystal G, Teitelbaum SL, Ross FP. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 2002, 8:943-949. 10.1038/nm752, 12161749.
48. Zhou P, Kitaura H, Teitelbaum SL, Krystal G, Ross FP, Takeshita S. SHIP1 negatively regulates proliferation of osteoclast precursors via Aktdependent alterations in D-type cyclins and p27. J Immunol 2006, 177:8777-8784.
49. Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal 2010, 3:ra38. 10.1126/scisignal.2000500, 2900152, 20484116.
50. Yamada T, Yamazaki H, Yamane T, Yoshino M, Okuyama H, Tsuneto M, Kurino T, Hayashi S, Sakano S. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood 2003, 101:2227-2234. 10.1182/blood-2002-06-1740, 12411305.
51. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 2008, 283:6509-6518. 10.1074/jbc.M707000200, 18156632.
52. Fukushima H, Nakao A, Okamoto F, Shin M, Kajiya H, Sakano S, Bigas A, Jimi E, Okabe K. The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol 2008, 28:6402-6412. 10.1128/MCB.00299-08, 2577420, 18710934.
53. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008, 14:306-314. 10.1038/nm1716, 2740725, 18297083.
54. Engin F, Yao Z, Yang T, Zhou G, Bertin T, Jiang MM, Chen Y, Wang L, Zheng H, Sutton RE, Boyce BF, Lee B. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 2008, 14:299-305. 10.1038/nm1712, 2671578, 18297084.
55. Zanotti S, Canalis E. Notch and the skeleton. Mol Cell Biol 2010, 30:886-896. 10.1128/MCB.01285-09, 2815558, 19995916.
56. Lee J, Kim K, Kim JH, Jin HM, Choi HK, Lee SH, Kook H, Kim KK, Yokota Y, Lee SY, Choi Y, Kim N. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 2006, 107:2686-2693. 10.1182/blood-2005-07-2798, 1895380, 16322470.
57. Chan AS, Jensen KK, Skokos D, Doty S, Lederman HK, Kaplan RN, Rafii S, Rivella S, Lyden D. Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS One 2009, 4:e7955. 10.1371/journal.pone.0007955, 2776978, 19956687.
58. Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, Ostrowski MC. Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors. Mol Cell Biol 2007, 27:4018-4027. 10.1128/MCB.01839-06, 1900027, 17403896.
59. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007, 109:3253-3259. 10.1182/blood-2006-09-048249, 17158225.
60. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, Miyamoto K, Hao W, Yoshida S, Morioka H, Chiba K, Kato S, Tokuhisa T, Saitou M, Toyama Y, Suda T, Miyamoto T. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010, 207:751-762. 10.1084/jem.20091957, 2856022, 20368579.
61. Kurowska-Stolarska M, Distler JH, Jüngel A, Rudnicka W, Neumann E, Pap T, Wenger RH, Michel BA, Müller-Ladner U, Gay RE, Maslinski W, Gay S, Distler O. Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum 2009, 60:3663-3675. 10.1002/art.25001, 19950294.
62. Yuen HF, Chiu YT, Chan KK, Chan YP, Chua CW, McCrudden CM, Tang KH, El-Tanani M, Wong YC, Wang X, Chan KW. Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1. Br J Cancer 2010, 102:332-341. 10.1038/sj.bjc.6605480, 2816654, 20010941.
63. Nishikawa K, Nakashima T, Hayashi M, Fukunaga T, Kato S, Kodama T, Takahashi S, Calame K, Takayanagi H. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci USA 2010, 107:3117-3122. 10.1073/pnas.0912779107, 2840297, 20133620.
64. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163. 10.1038/nm1538, 17237793.
65. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585. 10.1359/jbmr.090320, 19338457.
66. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002, 2:389-406. 10.1016/S1534-5807(02)00157-0, 11970890.
67. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005, 280:21162-21168. 10.1074/jbc.M501900200, 15802266.